Novonesis Achieves 9% Organic Sales Growth in H1; Full-Year Outlook Adjusted to 6-8% Range

Sales Growth and Outlook: Novonesis reported a 9% organic sales growth in H1 2025, with the full-year outlook for organic sales growth narrowed to 6-8%.

Market Performance: Strong performance was noted in both emerging markets (12% growth) and developed markets (8%), with Food & Health and Planetary Health segments also showing significant growth.

Financial Highlights: Adjusted EBITDA margin increased to 37.4%, adjusted net profit rose by 23%, and cost synergies reached a 100% run rate.

Future Strategy: The company announced its long-term financial targets towards 2030, which will be discussed in an upcoming conference call.